Neurology

Photo
30.10.2024 • News

AbbVie to Buy US Biotech Firm Aliada for $1.4 Billion

US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.

Photo
16.10.2024 • News

Lundbeck to Acquire Longboard Pharmaceuticals

Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.

Photo
02.09.2024 • News

UCB to Sell Neurology and Allergy Business in China

Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.

Photo
27.03.2023 • News

Bayer Plans to Scale Back Women’s Health R&D

Ahead of a change in leadership at the top after the upcoming annual general meeting, in interviews with news agencies Bayer is dropping hints in dribbles about future plans for its healthcare business.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.